The future of CD20 monoclonal antibody therapy in B-cell malignancies

References

• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas V.2. Available from: http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf. Accessed 15 September 2008.
   Google Scholar
• Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2006;66:791–820.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M, et al National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990–4997.
   PubMed Web of Science ®Google Scholar
• Zinzani PL. Lymphoma: diagnosis, staging, natural history, and treatment strategies. Semin Oncol 2005;32:S4–S10.
   PubMed Web of Science ®Google Scholar
• O'Connor O, Vose J. Getting the facts – indolent follicular lymphoma (updated March 2008). Lymphoma Research Foundation. Available from: http://www.lymphoma.org/atf/cf/%7B0363cdd6-51b5-427b-be48-e6af871acec9%7D/INDOLENT%20FOLLICULAR.PDF. Accessed 4 November 2008.
   Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, et al Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986–1992.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, et al CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–1423.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar
• Cao TM, Coutre SE. Management of advanced chronic lymphocytic leukemia. Curr Hematol Rep 2003;2:65–72.
   PubMedGoogle Scholar
• Leporrier M. Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia. Hematol J 2004;5(Suppl 1):S10–S19.
   PubMedGoogle Scholar
• Tam CS, O'Brien S, Lerner S, et al The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 2007;48:1931–1939.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Reyes F. Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective. Oncology (Williston Park) 2005;19:7–15.
   PubMedGoogle Scholar
• Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823–3837.
   PubMed Web of Science ®Google Scholar
• Kosmas C, Stamatopoulos K, Stavroyianni N, Tsavaris N, Papadaki T. Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia 2002;16:2004–2015.
   PubMed Web of Science ®Google Scholar
• Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007;67:1270–1281.
   PubMed Web of Science ®Google Scholar
• Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7:711–717.
   PubMed Web of Science ®Google Scholar
• Liu AY, Robinson RR, Murray ED, Jr., Ledbetter JA, Hellstrom I, Hellstrom KE. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol 1987;139:3521–3526.
   PubMed Web of Science ®Google Scholar
• Sieber T, Schoeler D, Ringel F, Pascu M, Schriever F. Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells. Br J Haematol 2003;121:458–461.
   PubMed Web of Science ®Google Scholar
• Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994;15:450–454.
   PubMedGoogle Scholar
• Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140–174.
   PubMedGoogle Scholar
• Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177–186.
   PubMed Web of Science ®Google Scholar
• Manches O, Lui G, Chaperot L, et al In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003;101:949–954.
   PubMed Web of Science ®Google Scholar
• Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000;51:634–641.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Liles TM, Czerwinski DK, et al Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457–2466.
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, et al Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435–445.
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Cittera E, Nota R, et al Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581–1587.
   PubMed Web of Science ®Google Scholar
• Golay J, Zaffaroni L, Vaccari T, et al Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900–3908.
   PubMed Web of Science ®Google Scholar
• Huhn D, von Schilling C, Wilhelm M, et al Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98:1326–1331.
   PubMed Web of Science ®Google Scholar
• Itala M, Geisler CH, Kimby E, et al Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol 2002;69:129–134.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725–3732.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M, et al Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088.
   PubMed Web of Science ®Google Scholar
• Tam CS, Wolf M, Prince HM, et al Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006;106:2412–2420.
   PubMed Web of Science ®Google Scholar
• Kay NE, Geyer SM, Call TG, et al Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405–411.
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-Lopez AJ, White CA, et al Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135–3143.
   PubMed Web of Science ®Google Scholar
• Rituximab. Prescribing information. 2006. Available from: http://www.fda.gov/cder/foi/label/2006/103705s5230-s5231lbl.pdf. Accessed February 2009.
   Google Scholar
• Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program 2007;2007:233–242.
   Google Scholar
• Cartron G, Dacheux L, Salles G, et al Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754–758.
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, et al The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362–371.
   PubMed Web of Science ®Google Scholar
• Macor P, Tripodo C, Zorzet S, et al In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007;67:10556–10563.
   PubMed Web of Science ®Google Scholar
• Treon SP, Mitsiades C, Mitsiades N, et al Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001;24:263–271.
   PubMed Web of Science ®Google Scholar
• van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006;12:4027–4035.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Olejniczak S, Gowda A, et al Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008;14:1561–1570.
   PubMed Web of Science ®Google Scholar
• D'Arena G, Musto P, Cascavilla N, Dell'Olio M, Di Renzo N, Carotenuto M. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol 2000;64:275–281.
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Kantarjian H, Thomas DA, et al Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165–2170.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• Zwick C, Gleissner B, Pfreundschuh M. Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma. Clin Lymphoma Myeloma 2007;8(Suppl. 2):S43–S49.
   PubMedGoogle Scholar
• Byrd JC, Peterson BL, Morrison VA, et al Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6–14.
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Wen S, et al Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070–4078.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fingerle-Rowson G, Fink A-M, et al First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group. Blood 2009;114(Suppl. 1): (Abstract 535).
   Google Scholar
• Lamanna N, Kalaycio M, Maslak P, et al Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006;24:1575–1581.
   PubMed Web of Science ®Google Scholar
• Faderl S, Thomas DA, O'Brien S, et al Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101:3413–3415.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Patton D, Gordon LI, et al A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 2004;45:2269–2273.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Castro J, O'Brien S, et al Comparison of results from a phase 1/2 study of lumiliximab (anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results. Blood 2006;108(Suppl. 1): (Abstract 32).
   Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti SB, et al Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103:4416–4423.
   PubMed Web of Science ®Google Scholar
• PRIMA study. Available from: http://clinicaltrials.gov/ct2/show/NCT00140582?term=PRIMA&rank=4. Accessed 7 May 2009.
   Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, et al Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003–4008.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, et al Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295–3301.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma–a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088–1095.
   PubMed Web of Science ®Google Scholar
• Cartron G, Solal-Celigny P. Maintenance therapy for low-grade lymphomas: has the time come? Curr Opin Oncol 2007;19:425–432.
   PubMed Web of Science ®Google Scholar
• Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004;103:2738–2743.
   PubMed Web of Science ®Google Scholar
• Cragg MS, Morgan SM, Chan HT, et al Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101:1045–1052.
   PubMed Web of Science ®Google Scholar
• Chan HT, Hughes D, French RR, et al CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003;63:5480–5489.
   PubMed Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS, et al Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793–1800.
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Gadeberg O, Johnson P, et al First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase I/II trial. Blood 2008;111:5486–5495.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Pedersen LM, et al Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111:1094–1100.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Durig J, et al Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial. Blood 2009;114(Suppl. 1): (Abstract 207).
   Google Scholar
• US National Institutes of Health. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ct2/results?term=ofatumumab+. Accessed 17 June 2009.
   Google Scholar
• GSK and Genmab receive accelerated approval for Arzerra™ (ofatumumab). Available from: http://www.genmab.com/PressCentre/RecentNewsReleases/39GSKandGenmabReceiveAcceleratedApprovalforArzerra/Language/English.aspx. Accessed 10 November 2009.
   Google Scholar
• Osterborg A, Kipps TJ, Mayer J, Stilgenbauer S, et al Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial. Blood 2008;112(Suppl. 1): (Abstract 328).
   Google Scholar
• Hagenbeek A, Fayad L, Delwail V, et al Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma. Blood 2009;114(Suppl. 1): (Abstract 935).
   Google Scholar
• Morschhauser F, Marlton P, Vitolo U, et al Interim results of a phase I/II study of ocrelizumab, a new humanised anti-CD20 antibody in patients with relapsed/refractory follicular non-Hodgkin's lymphoma. Blood 2007;110(Suppl. 1): (Abstract 645).
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Rossi EA, Stein R, et al Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009;113:1062–1070.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Leonard JP, Coiffier B, et al Initial safety and efficacy results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in non-Hodgkin's lymphoma. Blood 2005;106(Suppl. 1): (Abstract 2428).
   Google Scholar
• Leonard JP, Coleman M, Ketas JC, et al Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3051–3059.
   PubMed Web of Science ®Google Scholar
• Stein R, Qu Z, Chen S, et al Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004;10:2868–2878.
   PubMed Web of Science ®Google Scholar
• Weitzman J, Betancur M, Boissel L, Rabinowitz A, Klingemann H. Variable contribution of different monocloncal antibodies to NK cell-mediated ADCC against primary CLL cells. Blood 2007;110(Suppl. 1): (Abstract 4715).
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Leonard JP, Fayad L, et al Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol 2009;27:3346–3353.
   PubMed Web of Science ®Google Scholar
• Allen S, Rai K, Elstrom R, et al Subcutaneous injections of low doses of veltuzumab (humanized anti-CD20 antibody): objective responses in B-cell malignancies. J Clin Oncol 2009;27(Suppl.): Abstract 8530.
   Google Scholar
• Umana P, Moessner E, Bruenker P, et al Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. Blood 2006;108(Suppl. 1): (Abstract 229).
   Google Scholar
• Alduaij W, Potluri S, Ivanov A, et al New-generation anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell lymphoma. Blood 2009;114(Suppl. 1): (Abstract 725).
   Google Scholar
• Friess T, Gerdes C, Nopora A, et al GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death induction, mediates superior efficacy in a variety of NHL xenograft models in comparison to rituximab. Blood 2007;110(Suppl. 1): (Abstract 2338).
   Google Scholar
• Umana P, Ekkehard M, Peter B, et al GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death induction, exhibits superior anti-tumor efficacy and superior tissue B cell depletion in vivo. Blood 2007;110(Suppl. 1): (Abstract 2348).
   Google Scholar
• Patz M, Forcob N, Müller B, et al Depletion of chronic lymphocytic leukemia cells from whole blood samples mediated by the anti-CD20 antibodies rituximab and GA101. Blood 2009;114(Suppl. 1): (Abstract 2365).
   PubMed Web of Science ®Google Scholar
• Zenz T, Volden M, Mast T, et al In vitro activity of the type II anti-CD20 antibody GA101 in refractory, genetic high-risk CLL. Blood 2009;114(Suppl. 1): (Abstract 2379).
   PubMed Web of Science ®Google Scholar
• Salles G, Morschhauser F, Lamy T, et al Phase I study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ non-Hodgkin lymphoma (NHL). Blood 2009;114(Suppl. 1): (Abstract 1704).
   Google Scholar
• Sehn L, Assouline S, Stewart D, et al A phase I study of GA101 (RO5072759) monotherapy followed by maintenance in patients with multiply relapsed/refractory CD20+ malignant disease. Blood 2009;114(Suppl. 1): (Abstract 884).
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Cartron G, Lamy T, et al Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Blood 2009;114(Suppl. 1): (Abstract 884).
   Google Scholar
• Bowles JA, Wang S-Y, Link BK, et al Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006;108:2648–2654.
   PubMed Web of Science ®Google Scholar
• Weiner GJ, Bowles JA, Link BK, Campbell MA, Wooldridge JE, Breitmeyer JB. An anti-CD20 monoclonal antibody (mAb) with enhanced affinity for CD16 activates NK cells at a lower concentrations and more effectively than rituximab. Blood 2005;106(Suppl. 1): (Abstract 348).
   PubMed Web of Science ®Google Scholar
• Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res 2008;14:1550–1560.
   PubMed Web of Science ®Google Scholar
• Beum PV, Lindorfer MA, Beurskens F, et al Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008;181:822–832.
   PubMed Web of Science ®Google Scholar